Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Lyme Disease Testing Guidelines

Clinical Diagnosis and Testing

  • The Centers for Disease Control and Prevention recommends that patients with erythema migrans in endemic areas be diagnosed clinically without laboratory testing, as approximately 70-80% of Lyme disease patients present with this symptom 4, 5
  • Clinical diagnosis in this scenario avoids the window period problem where antibody testing has poor sensitivity (only 30-40%) during early infection, and accompanying symptoms may include fever, lymphadenopathy, myalgias, or arthralgias 1, 4, 5
  • For patients without EM or with suspected disseminated disease, the standard of care is two-tiered serologic testing: first-tier EIA or IFA, followed by reflex Western immunoblot only if the first test is positive or equivocal, as recommended by the Infectious Diseases Society of America 1, 2, 4

Test Performance Characteristics

  • Two-tiered testing has sensitivity of 70-100% and specificity >95% for disseminated Lyme disease, but sensitivity drops to only 30-40% during early localized infection, according to the Centers for Disease Control and Prevention 1, 5
  • For early disease with EM in acute phase: sensitivity is only 40%, but improves to 61% in the convalescent phase (3-4 weeks later) 7, 8
  • For disseminated disease (neuritis, carditis, arthritis): sensitivity reaches 88-100% 7, 8

Critical Pretest Probability Considerations

  • Geographic exposure history is the most crucial factor determining whether to test—even highly specific tests produce false-positives when pretest probability is low, as noted by the Centers for Disease Control and Prevention 9
  • In low-incidence states without recent travel to endemic areas, positive predictive value is only 10%, and only 0.7% of patients in non-endemic areas with arthritis, cranial neuropathies, or meningitis actually have Lyme disease 9

Common Pitfalls to Avoid

  • Never order Western immunoblot without first performing EIA/IFA—this dramatically increases false-positive rates, as warned by the Infectious Diseases Society of America 9
  • Avoid urine antigen tests and CD57 tests, which lack validation, and do not retest patients after treatment—antibodies persist for months to years after successful treatment and do not indicate active infection, according to the Infectious Diseases Society of America 9, 10